Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.

Fedier, André; Maggi, Nadia; Tozzi, Alessandra; Disler, Muriel; Coelho, Ricardo; Jacob, Francis; Heinzelmann-Schwarz, Viola

Fedier, André; Maggi, Nadia; Tozzi, Alessandra; Disler, Muriel; Coelho, Ricardo; Jacob, Francis; Heinzelmann-Schwarz, Viola.

Afiliação

Fedier A; Ovarian Cancer Research Program, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Maggi N; Ovarian Cancer Research Program, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Tozzi A; Hospital for Women, Department of Gynecology and Gynecological Oncology, Women's Hospital, University Hospital Basel, University of Basel, 4021 Basel, Switzerland.
Disler M; Ovarian Cancer Research Program, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Coelho R; Ovarian Cancer Research Program, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Jacob F; Ovarian Cancer Research Program, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Heinzelmann-Schwarz V; Ovarian Cancer Research Program, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Int J Oncol ; 61(1)2022 Jul.

Article em En | MEDLINE | ID: mdl-35642662

Assuntos

Resistencia a Medicamentos Antineoplásicos; Neoplasias Ovarianas; Inibidores de Poli(ADP-Ribose) Polimerases; Antineoplásicos Alquilantes/farmacologia; Linhagem Celular Tumoral; Doxorrubicina/farmacologia; Feminino; Humanos; Neoplasias Ovarianas/tratamento farmacológico; Paclitaxel/farmacologia; Ftalazinas/farmacologia; Piperazinas/farmacologia; Compostos de Platina/farmacologia; Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia

Palavras-chave

acquired resistance; anthracyclines; chemosensitivity; crossresistance; multidrug resistance; ovarian cancer; paclitaxel; platinum; poly (ADPribose) polymeraseinhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Resistencia a Medicamentos Antineoplásicos / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Int J Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google